Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Xenon Pharmaceuticals excels in Q3, poised for groundbreaking treatments

Xenon Pharmaceuticals demonstrated strong financial performance and progress in developing azetukalner for epilepsy and major depressive disorder.
Confidence in the lead product's potential for groundbreaking treatments was evident, supported by ongoing outreach efforts and future milestones.
While facing challenges in addressing complex analyst inquiries and navigating regulatory requirements, Xenon Pharmaceuticals is well-positioned to capitalize on opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences.

Xenon to Present at Upcoming Investor Conferences

XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Caroline Pocher - JPMorgan Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Luke Herrmann - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Paul Choi - Goldman Sachs Danielle Brill - Raymond James Marc Goodman - Leerink Partners Joseph Thome - TD Cowen Dylan Shindler - Wedbush Securities Operator Good afternoon, and thank you for standing by. At this time, I'd like to welcome everyone to Xenon Pharmaceuticals, Inc. Third Quarter 2024 Earnings Conference Call.

Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript

– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 – Recent appointment of Matt Ronsheim, experienced pharmaceutical executive joining Xenon's senior executive team as Chief Operating Officer – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today provided a business update and reported financial results for the third quarter ended September 30, 2024. “Xenon's leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium channel opener in development for multiple indications that is backed by long-term efficacy and safety data with over 600-patient years of exposure in patients living with epilepsy.

Xenon Reports Q3 2024 Financial Results and Business Update

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024.

Xenon to Report Q3 2024 Financial Results on November 12, 2024

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024.

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced three poster presentations at the 15th European Epilepsy Congress (EEC) taking place in Rome, Italy. Azetukalner, a novel, potent Kv7 channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage development for multiple indications, including focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS) and major depressive disorder (MDD).

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has appointed Dr Chase Hall as chief medical advisor. An associate professor at the University of Kansas Medical Center, Hall specialises in pulmonary care and imaging biomarkers using Xenon MRI.

Polarean Imaging appoints Xenon MRI specialist as its chief medical advisor

Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.

Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe

Xenon Pharmaceuticals, Inc. (NASDAQ:XENE ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Chad Fugere - VP, IR Ian Mortimer - President & CEO Chris Kenney - CMO Sherry Aulin - CFO Chris Von Seggern - CCO Conference Call Participants Paul Matteis - Stifel Leo Leung - RBC Capital Markets Tessa Romero - J.P. Morgan Dina Ramadane - Bank of America Luke Herrmann - Baird Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Peyton Bohnsack - TD Cowen Dylan Shindler - Wedbush Securities Basma Radwan - Leerink Partners Operator Thank you for standing by.

Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript

Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 — MDD program on track with Phase 3 study expected to initiate in H2 2024—  Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025—  Conference call at 4:30 pm ET today

Xenon Reports Q2 2024 Financial Results and Business Update

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: Date: Thursday, August 8, 2024 Time: 4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963 for international callers Conference ID: 1631616     The live audio webcast can be accessed on the Investors section of the Xenon website.

Xenon to Report Q2 2024 Financial Results on August 8, 2024

Global Xenon Gas Market Report 2024-2034: Aerospace & Aircraft Industry Emerges as the Leading Consumer, with Significant Usage in Satellite Propulsion. The healthcare industry, a sector witnessing exponential global investment, presents substantial market opportunities for xenon gas manufacturers. Global Xenon Gas Market Report 2024-2034: Aerospace & Aircraft Industry Emerges as the Leading Consumer, with Significant Usage in Satellite Propulsion. The healthcare industry, a sector witnessing exponential global investment, presents substantial market opportunities for xenon gas manufacturers.

Xenon Gas Market to Reach USD 270.5 Million at a CAGR of 5.2% through 2034 Amid Bolstering Usage in MRI Scanning Machines and High-power Lamps | Future Market Insights, Inc.

VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL.

Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) announced its latest new order for a Xenon MRI System, from the University of Alabama at Birmingham (UAB) Hospital. The order from the hospital, a top-tier academic institution in the southeastern United States, extends the company's innovative imaging technology to an additional major hospital for the first time, Polarean noted.

Polarean Imaging lands new hospital order for Xenon MRI System

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024

Featured Company at Respiratory Innovation Summit to Jump Start Robust Presence Featured Company at Respiratory Innovation Summit to Jump Start Robust Presence

Polarean's Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), a leader in advanced MRI technology, has been selected as a featured company and poster presenter at the upcoming American Thoracic Society's 2024 Respiratory Innovation Summit. A key gathering for those involved in pulmonary medicine, the event, which takes place from May 17-18 in San Diego, brings together over 275 global leaders from various sectors including start-ups, venture capital, and academia.

Polarean Imaging to showcase Xenon MRI at Respiratory Innovation Summit

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY.

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock

VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024.

News for Xenon Pharmaceuticals Stock (XENE)